Dr Goran Petrovski graduated the Medical School in Skopje, Macedonia, in 1997. His background as Professor and Endocrinologist comprises treatment of 620 patients on insulin pumps, evaluation of 600.000 sensor glucose days, 54 personalized insulin pump workshops for physicians and educators, and keynote addresses as a speaker or invited lecturer at international conferences on diabetes technology in Europe, USA, the Middle East, Asia and Africa. He is also a Visiting Professor at several medical schools in Europe and Asia.
Goran was active medical student as the President of National Association and chief of the student journal. His initial endocrine training was in Skopje with fellowships in USA, France and Italy. His Master of Science thesis was on male infertility in 2003, and his PhD thesis was on Insulin Pump and Sensors in 2006. He was promoted to Professor at the Medical Faculty in Skopje in 2012. He is Donnell D. Etzwiler Scholar at the International Diabetes Center in Minneapolis and the Mayo Clinic in Rochester, USA, and Lantus Young Investigator prize winner for clinical research in 2009 in Berlin, Germany.
He started the national insulin pump program in 2002 and, as head of the Center for Insulin Pumps and Sensors, from 2011 has achieved the reimbursement of insulin pump and sensors in his home country. He was very active in publishing and promoting diabetes technology in the region and abroad, and also serves as volunteer on Diabetes Summer Camps.
Goran's research interest focuses on type 1 diabetes, insulin pumps and continuous glucose monitoring. He has published more than 180 papers in peer-reviewed journals, international conferences and has authored four books on type 1 diabetes, insulin pumps, endocrinology tests and clinical examinations. As a Professor of Clinical Medicine at both Ss Cyril and Methodius University, Macedonia, and Weill Cornell Medical College, USA, he has the opportunity to transmit clinical research to students, residents and fellows. He is also active in performing clinical trials in diabetes.
His goal is to decrease A1c levels by 1.5% in every uncontrolled patient with type 1 diabetes for a period of one year, until he/she reaches satisfied glucose control.